A phase II study combining gemcitabine and carboplatin in patients with platinum-resistant ovarian cancer
Not Applicable
- Conditions
- patients with platinum-resistant ovarian cancer
- Registration Number
- JPRN-UMIN000019225
- Lead Sponsor
- Osaka medical coledge
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
The organization type including sarcoma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method clinical responce
- Secondary Outcome Measures
Name Time Method side effect